Hepatocellular Carcinoma

Localized

IRB# 20744
Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

No Prior Therapy

IRB# 23365
A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients with unresectable and locally-advanced HCC

Prior Therapy

IRB# 20929
Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARIMAB) for the treatment of advanced hepatocellular carcinoma

No Trials Currently Available

Cholangiocarcinoma

1st Line

IRB# 20357
[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB# 16033
Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

2nd Line or more

IRB# 20929
No Trials Currently Available

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

KEY

<table>
<thead>
<tr>
<th>Open to Enrollment</th>
<th>In Development</th>
<th>Enrollment on Hold</th>
</tr>
</thead>
</table>

02 MAY 2022

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial